Yeh Susan, Smith Peter J, Chibale Kelly
Division of Pharmacology, Department of Medicine, University of Cape Town Medical School, Observatory 7925, South Africa.
Biochem Pharmacol. 2006 Jul 14;72(2):156-65. doi: 10.1016/j.bcp.2006.04.006. Epub 2006 Apr 25.
On the basis of structural features known to be critical for the antimalarial activity, accumulation and uptake of chloroquine (CQ), as well as chemosensitization of CQ resistant Plasmodium falciparum, an exploratory novel series of potential dual acting antiplasmodial and chemosensitizing agents was designed and synthesized for biological evaluation. All four compounds contain a common alkyl side chain with two amino groups and differ only in the chemical nature of the hydrophobic aromatic moieties. Among them, N'-[4-(biphenyl-2-ylmethoxy)-benzyl]-N,N-dimethyl-propane-1,3-diamine (P7) displayed the greatest potential as a dual-acting antiplasmodial agent against CQ-resistant strains (IC50K1/RSA11<0.6 microM) and chemosensitizer (RMIK1=0.67; RMIRSA11=0.82) while displaying low in vitro cytotoxicity against a mammalian cell line (CHO). At 1 microM, P7 caused a 8.5 and 4-fold potentiation in CQ accumulation in resistant P. falciparum K1 and RSA11 strains, respectively. In a parallel experiment, 1 microM verapamil showed a 6.5 (K1) and 2 (RSA11)-fold increase in CQ accumulation. The preliminary studies point to structural features that may determine antiplasmodial and/or CQ resistance modulating activity in this new series of compounds. An additive effect was observed against both CQS (D10) and CQR (RSA11) strains when CQ and P7 were used at their corresponding IC50 concentrations in isobologram analysis.
基于已知对氯喹(CQ)的抗疟活性、积累和摄取以及对耐CQ恶性疟原虫的化学增敏作用至关重要的结构特征,设计并合成了一系列探索性的新型潜在双作用抗疟和化学增敏剂,用于生物学评估。所有四种化合物都含有一个带有两个氨基的共同烷基侧链,仅在疏水芳香部分的化学性质上有所不同。其中,N'-[4-(联苯-2-基甲氧基)-苄基]-N,N-二甲基丙烷-1,3-二胺(P7)作为针对耐CQ菌株的双作用抗疟剂(IC50K1/RSA11<0.6 microM)和化学增敏剂(RMIK1=0.67;RMIRSA11=0.82)显示出最大潜力,同时对哺乳动物细胞系(CHO)表现出低体外细胞毒性。在1 microM时,P7分别使耐CQ的恶性疟原虫K1和RSA11菌株中CQ的积累增强了8.5倍和4倍。在平行实验中,1 microM维拉帕米使CQ积累增加了6.5倍(K1)和2倍(RSA11)。初步研究指出了可能决定这一系列新化合物抗疟和/或CQ抗性调节活性的结构特征。在等效线图分析中,当CQ和P7以其相应的IC50浓度使用时,观察到对CQS(D10)和CQR(RSA11)菌株均有相加作用。